EUVIMEDEUVIMED entdecken
Crossref

Clinical efficacy of CFTR modulator therapy in people with cystic fibrosis carrying the I1234V mutation

Bat El Bar Aluma, Joel Reiter, Ori Efrati, Yael Bezalel, Shlomit Keler, Moshe Ashkenazi, Adi Dagan, Yael Buchnik, Ido Sadras, Malena Cohen-Cymberknoh

Journal of Cystic Fibrosis · 2024

DOI: 10.1016/j.jcf.2024.02.008 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cystic Fibrosis, 2024. Verfasst von Bat El Bar Aluma und 9 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Pulmonary Unit and Cystic fibrosis Center, Lily and Edmond Safra Children's Hospital, Sheba Medical Center, Faculty of Medicine, Tel Aviv U…. Hauptthemen laut MEDLINE: Cystic Fibrosis, Cystic Fibrosis Transmembrane Conductance Regulator, Benzodioxoles, Aminophenols. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The cystic fibrosis transmembrane conductance regulator (CFTR) mutation I1234V (I1234V, p.Ile1234Val, c.3700A>G), is a missense-mutation that creates a cryptic splice site, with the formation of a protein lacking 6 amino acids, that is misfolded and misprocessed. The in vitro effects of CFTR modulator (CFTRm) therapies on human bronchial cell models and intestinal organoids carrying this mutation are conflicting. The aim of this study was therefore to explore the clinical efficacy of CFTRm in people with cystic fibrosis (pwCF) carrying this mutation. METHODS: This was a retrospective descriptive study of the clinical records of homozygous and compound heterozygous (none F508del) pwCF, for the I1234V mutation, that received CFTRm. Parameters explored were body mass index (BMI), forced expiratory volume in one second percent predicted (FEV1%), lung clearance index (LCI) and quantitative sweat chloride measurements. RESULTS: Mean age was 38.6 ± 14 years (range 21-60). Two subjects were homozygous and five compound heterozygous, with minimal function mutations. Four were pancreatic insufficient and three pancreatic sufficient. The two homozygous subjects received Tezacaftor/Ivacaftor, the remaining Elexacaftor/Tezacaftor/Ivacaftor (ETI); treatment ranged from 6 to 12 months. Mean BMI score increased from 21.7 ± 1.3 to 23.6 ± 2.1 kg/m2 (p = 0.04); FEV1(%pred) increased by 20.14±10.2while mean change in FEV1 in the year prior to CFTRm initiation was -0.14±1.18 (p = 0.0001). Additionally, LCI 2.5% decreased from 18.7 to 14.5 (p = 0.07); sweat chloride decreased from 116±10 to 90±17 mEq/L (p = 0.017) and chronic pseudomonas airway infection was eradicated in one subject. CONCLUSIONS: This study supports a clinical benefit for CFTRm therapy in pwCF carrying the I1234V mutation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorBenzodioxolesAminophenolsHumansMaleFemaleRetrospective StudiesAdultQuinolonesAminopyridinesIndolesChloride Channel AgonistsTreatment OutcomeDrug CombinationsMutation, MissenseForced Expiratory VolumeSweat

Stichwörter der Autor:innen

CFTR modulatorsElexacaftor/Tezacaftor/IvacaftorI1234V CFTR mutation

Substanzen

Cystic Fibrosis Transmembrane Conductance RegulatorBenzodioxolesAminophenolsQuinolonesAminopyridinesIndolesChloride Channel AgonistsDrug Combinationstezacaftorivacaftor

Autor:innen und Institutionen

  • Pediatric Pulmonary Unit and Cystic fibrosis Center, Lily and Edmond Safra Children's Hospital, Sheba Medical Center, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. Electronic address: batel.baraluma@sheba.…
  • Pediatric Pulmonary Unit and Cystic fibrosis Center, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, Israel.
  • Pediatric Pulmonary Unit and Cystic fibrosis Center, Lily and Edmond Safra Children's Hospital, Sheba Medical Center, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Zitieren

APA

Aluma, B. E. B., Reiter, J., Efrati, O., Bezalel, Y., Keler, S., Ashkenazi, M., Dagan, A., Buchnik, Y., Sadras, I., & Cohen-Cymberknoh, M. (2024). Clinical efficacy of CFTR modulator therapy in people with cystic fibrosis carrying the I1234V mutation. Journal of Cystic Fibrosis. https://doi.org/10.1016/j.jcf.2024.02.008

Vancouver

Aluma BEB, Reiter J, Efrati O, Bezalel Y, Keler S, Ashkenazi M, et al. Clinical efficacy of CFTR modulator therapy in people with cystic fibrosis carrying the I1234V mutation. Journal of Cystic Fibrosis. 2024. doi:10.1016/j.jcf.2024.02.008

BibTeX
@article{Aluma2024,
  author = {Aluma, Bat El Bar and Reiter, Joel and Efrati, Ori and Bezalel, Yael and Keler, Shlomit and Ashkenazi, Moshe and Dagan, Adi and Buchnik, Yael and Sadras, Ido and Cohen-Cymberknoh, Malena},
  title = {Clinical efficacy of CFTR modulator therapy in people with cystic fibrosis carrying the I1234V mutation},
  journal = {Journal of Cystic Fibrosis},
  year = {2024},
  doi = {10.1016/j.jcf.2024.02.008}
}
Kostenlos starten →